Grifols SA (GRFS)
About Grifols SA
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $5.2B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $5.2B
- Shares outstanding
- 686.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 2, 2011
Grifols SA (GRFS) Stock Price
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Grifols SA.
Write a review
News about Grifols SA
News & sentiment via Polygon.io
Grifols SA: frequently asked questions
Is Grifols SA an American company?
Grifols SA is a US-based company headquartered in New York, New York, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Grifols SA headquartered?
Grifols SA is headquartered in New York, New York, United States.
Is Grifols SA publicly traded?
Yes — Grifols SA is a publicly traded company. Its stock trades under the ticker symbol GRFS on the NASDAQ.
What does Grifols SA do?
Grifols SA is an American Pharmaceuticals company in the Health & Beauty sector.
